Masterclass:
Biotech Dealmaking and IP Licensing
The OBIO® Biotech Dealmaking and IP Licensing Masterclass, delivered in collaboration with BioLabs – University of Toronto and Novateur Ventures, is an intensive, hands-on training program designed to help early-stage biotech teams strategically position their pre-clinical assets for pharma partnerships and non-dilutive licensing deals.
Over 2.5 days, participants will gain practical insights into deal structures, asset valuation, AI-driven diligence, and the impact of Most Favoured Nation (MFN) pricing. The program will culminate in a live mock negotiation, giving participants an opportunity to put what they have learned into practice with seasoned pharma dealmakers.
Who Should Attend
This Masterclass is designed for early-stage and pre-clinical biotech team members who are leading partnering conversations without the support of a large corporate BD department:
» Founders, CEOs, and CSOs preparing for their first strategic alliance or licensing deal
» Senior R&D and operational biotech leaders building data rooms or supporting pharma due diligence
» Emerging biotech BD leads looking to benchmark their valuation and negotiation strategy
What Makes This Masterclass Different
» Learn directly from a global pharma BD executives, life science investors and IP counsel.
» Get practical, small-group coaching and feedback on your asset strategy.
» Participate in a case study and live negotiation, working in small teams to value a pre-clinical/IND-stage asset and negotiate a term sheet in real time.
-
Overview of the dealmaking work scope & process from a founder's perspective
How corporate venture and BD external innovation inside Big Pharma is organized and how decisions actually get made
Categories of strategic alliances and trade-offs of each (research collaborations, platform vs. asset licensing, acquisitions, university tech transfer)
-
Identifying the right corporate partners and making initial contact
Running successful partnering meetings and managing internal/board stakeholder expectations
Structuring your outreach collateral: Non-confidential 'Pitch' deck, 'Follow-up' deck, and 'Confidential' presentation
What to include vs. exclude in non-confidential disclosures
How AI is reshaping asset sourcing and early-stage screening
-
Managing disclosure throughout the lifecycle of a partnership
Key areas of caution when signing a mutual CDA and defining post-CDA data sharing scope
IP considerations for novel technologies and managing data rights around key milestones
Patent strategy: timing, local vs. international filing, enforcement, and M&A/licensing readiness
Working through a Technology Evaluation Agreement (TEA)
-
Why diligence matters and how to build a clean, pharma-ready data room structure
Due diligence checklist, common founder pitfalls, and dealbreakers to avoid
Managing due diligence from biotech, pharma, and legal perspectives
-
In-licensing vs. out-licensing and structuring deals for biotech value creation
Roles and incentives of all players at the table (founders, pharma buyers, VCs, board members)
Key elements of a term sheet and deal structures (upfronts, milestones, royalties)
Process flow and realistic timelines from first call to close
Spotting favourable and unfavourable terms on a term sheet
In 2027 what has changed with upfront and milestone based payments, and royalties
-
Defining your Target Product Profile (TPP) to anchor asset value
Patient-based revenue forecasting, expense forecasting, and calculating risk-adjusted NPV (rNPV)
Scientific and market parameters that move valuation multiples
Navigating US Most Favoured Nation (MFN) drug pricing impacts on deal valuation
-
Finding the right cultural and strategic partner fit
Engagement tactics, soft skills, and navigating live negotiations
Post-close alliance management: keeping the partnership on track after the ink dries
Real-world legal pitfalls taught through actual deal post-mortems
-
Global Pharma Speakers: Hearing directly from pharma BD teams on what they are actively hunting for
Immersive Team Case Study: Working on a mock biotech with a platform-derived preclinical asset and an IND-stage asset
Live mock term sheet negotiation across the table from global pharma dealmakers
Pricing (2.5 day masterclass): $1,600+HST
Including breakfast & lunch during the course and
private networking opportunity with pharma guest speakers.